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Summary
Background: Irritable	bowel	syndrome	with	diarrhoea	(IBS‐D)	is	a	common	condition,	
greatly	reducing	the	quality	of	life	with	few	effective	treatment	options	available.
Aims: To	 report	 the	 beneficial	 response	 shown	 in	 our	 trial	 with	 the	 5‐hydroyx‐
tryptamine	(5‐HT)	receptor	3	antagonist,	ondansetron	in	IBS‐D
Methods: A	randomised,	placebo‐controlled,	cross‐over	trial	of	5	weeks	of	ondan‐
setron	versus	placebo	in	125	patients	meeting	modified	Rome	III	criteria	for	IBS‐D	
as	previously	described.	Patients	were	compared	to	21	healthy	controls.	5‐HT	and	
5‐HIAA	were	measured	in	rectal	biopsies.	Whole	gut	transit	time	was	assessed	using	
a	radio‐opaque	marker	technique.	Whole	blood	DNA	was	genotyped	for	an	insertion	
polymorphism	in	the	promoter	region	of	the	serotonin	transporter	gene	SLC6A4,	as	
well	as	single	nucleotide	polymorphisms	(SNPs)	of	the	tryptophan	hydroxylase	gene	
TPH1	and	5‐HT3	receptor	genes	HTR3A, C and E.
Results: Patients’	 biopsies	 showed	significantly	higher	5‐HIAA	 levels	 (2.1	 (1.2‐4.2)	
pmol/mg	protein	vs	1.1	(0.4‐1.5)	in	controls,	P	<	.0001).	39	patients	used	<	4	mg/d	
(“super‐responders”)	while	55	required	≥	4	mg/d.	5‐HT	concentrations	in	rectal	biop‐
sies	were	significantly	lower	in	super‐responders	(21.3	(17.0‐31.8)	vs	37.7	(21.4‐61.4),	
P	=	.0357)	and	the	increase	in	transit	time	on	ondansetron	was	significantly	greater	
(15.6	(1.8‐31)	hours	vs	3.9	(−5.1‐17.9)	hours).	Stool	consistency	responders	were	more	
likely	to	carry	the	CC	genotype	of	the	SNP	p.N163K	rs6766410	of	the	HTR3C	gene	
(33%	vs	14%,	P	=	.0066).
Conclusion: IBS‐D	patients	have	significant	abnormalities	 in	mucosal	5‐HT	metab‐
olism.	Those	with	 the	 lowest	concentration	of	5‐HT	 in	 rectal	biopsies	showed	the	
greatest	responsiveness	to	ondansetron.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
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1  | INTRODUC TION
When	patients	with	irritable	bowel	syndrome	with	diarrhoea	(IBS‐D)	
are	asked	to	report	their	most	bothersome	symptoms,	erratic	bowel	
habit	and	urgency	are	the	most	common.1	Urgency	and	the	associated	
occasional	faecal	incontinence	cause	significant	distress	and	anxiety,	
which	substantially	impair	their	quality	of	life.	Serotonin	(5‐hydroxy‐
tryptamine	 (5‐HT)),	 a	 neurotransmitter	 in	 the	 gut	 has	many	 effects	
which	are	relevant	to	this	aspect	of	IBS,	stimulating	intestinal	secre‐
tion and colonic motility.2	5‐HT	3	(5‐HT3)	receptor	antagonists	includ‐
ing	alosetron,	cilansetron	and	ramosetron	which	block	these	effects	
and	slow	whole	gut	transit	have	been	shown	 in	meta‐analysis	 to	be	
effective	treatments	for	IBS‐D.3	Alosetron	was	withdrawn	because	of	
adverse	events	including	severe	constipation	and	ischaemic	colitis.4 It 
has	now	been	reintroduced	under	a	FDA‐managed	risk	evaluation	and	
mitigation	strategy	but	is	not	widely	used.	Ramosetron,	a	potent	highly	
specific	5‐HT3	receptor	antagonist	has	been	shown	to	be	similarly	ef‐
fective	and	recently	another	5‐HT3	receptor	antagonist,	ondansetron,	
has	also	been	shown	to	be	effective	without	causing	ischaemic	colitis.
Our	 previous	 studies	which	 focused	 on	 post‐infectious	 IBS	 (PI‐
IBS),	two‐thirds	of	whom	have	IBS‐D,	had	shown	an	increased	number	
of	5‐HT	containing	enteroendocrine	cells.5	We	also	showed	in	animal	
models	of	PI‐IBS6	 that	colonic	mucosal	5‐HT	was	elevated	 immedi‐
ately	after	infection	and	5‐hydroxyindole	acetic	acid	(5‐HIAA)/5‐HT	
ratios	were	 increased	while,	serotonin	transporter	gene	(SERT	gene	
SLC6A4)	mRNA	expression	was	depressed	up	to	56	days	post‐infec‐
tion,	these	two	changes		suggesting	long‐lasting	accelerated	mucosal	
5‐HT	turnover.	This	was	associated	with	enhanced	firing	of	afferent	
neurons	during	colonic	distension,	a	feature	which	could	be	blocked	
by	ondansetron.	This	led	us	to	hypothesise	that	increased	5‐HT	avail‐
ability	in	the	intestinal	mucosa	could	be	the	driver	of	symptoms	and	
the	explanation	of	the	benefit	of	5‐HT3	receptor	antagonists	in	IBS‐D.
There	are	marked	individual	differences	in	responsiveness	to	5‐
HT3	receptor	antagonists	which	have	been	correlated	with	common	
polymorphisms	in	key	genes	governing	the	synthesis	and	reuptake	of	
5‐HT,	as	well	as	the	structure	of	the	5‐HT	receptors.	Responsiveness	
to	alosetron	was	 shown	 in	one	 trial	 to	be	greater	with	 the	homo‐
zygous	 l/l	 variant	 of	 the	 5‐HTTLPR	 (serotonin‐transporter‐linked	
polymorphic	 region)	 of	SLC6A4.7	 Furthermore,	 the	 gene	TPH1 en‐
coding	tryptophan	hydroxylase	1,	the	rate	limiting	enzyme	for	sero‐
tonin	synthesis	in	enterochromaffin	cells	of	the	gut,	contains	several	
single	 nucleotide	 polymorphisms	 (SNPs),	 including	 rs4537731	 and	
rs211105,	which	have	been	 reported	 to	predict	 responsiveness	 to	
ramosetron.8	 Finally,	 the	 SNP	 of	HTR3C	 p.N163K	 rs6766410	 pre‐
dicts	chemotherapy‐induced	vomiting,9	which	is	known	to	be	driven	
largely	by	serotonin.	This	led	us	to	hypothesize	that	the	sensitivity	to	
ondansetron	might	in	part	be	dependent	on	genetic	variability	due	
to	polymorphisms	in	these	genes.
We	 now	present	 the	 biomarkers	 of	mucosal	 5‐HT	metabolism	
along	with	the	genetic	markers	obtained	from	patients	participating	
in	our	double‐blind	cross‐over	trial	whose	clinical	results	have	been	
previously	reported,10	aiming	to	further	characterise	IBS‐D	patients	
who	respond	to	ondansetron	therapy.
2  | MATERIAL S AND METHODS
2.1 | Design
The	design	was	as	previously	described.10	In	brief,	125	patients	with	
IBS‐D	meeting	Rome	III	criteria11	were	recruited	from	gastroenterol‐
ogy	 clinics	 in	Nottingham	 and	Manchester	 and	 randomised	 to	 re‐
ceive	either	5	weeks	of	ondansetron,	 then	5	weeks	of	placebo	or	
placebo	followed	by	ondansetron,	with	at	least	2	weeks	washout	be‐
tween	the	two	treatment	periods.	Doses	were	titrated	for	the	first	
3	weeks	of	each	treatment	period,	maintaining	a	constant	dose	for	
the	final	2	weeks.	Twenty‐one	healthy	volunteers	were	recruited	as	
controls	 for	comparison.	They	completed	the	same	questionnaires	
as	 IBS‐D	patients,	 underwent	 rectal	mucosal	 biopsy	 and	provided	
normal	values	for	colonic	transit	studies.
2.2 | Data collection
The	 following	 personal	 baseline	 data	 were	 collected:	 age,	 sex,	
Hospital	 Anxiety	 and	 Depression	 Scale	 (HADS)12	 score,	 Patient	
Health	Questionnaire	 12	 Somatic	 Symptom	 (PHQ‐12)13	 score	 and	
Perceived	Stress	Scale14	score.	 IBS	Quality	of	Life	Questionnaire15 
and	 IBS	 Severity	 Scoring	 System16	 scores	were	 collected	 at	 base‐
line	and	at	the	end	of	each	treatment	period.	A	previously	described	
daily	stool	diary17	was	used	to	collect	stool	form	information	(using	
the	Bristol	 Stool	 Form	Score	 (BSFS),18	 abdominal	 pain	 perception,	
urgency	 to	defecate	and	abdominal	bloating	 (all	 three	scored	on	a	
0‐3	scale).	Frequency	of	defecation	and	number	of	days	with	bloat‐
ing,	 pain	 or	 urgency	 were	 recorded.	 Whole	 gut	 transit	 time	 was	
measured	after	5	weeks	of	each	treatment	using	the	Metcalf's	radio‐
opaque	marker	technique.19
2.3 | Biopsy analysis
All	70	patients	recruited	from	Nottingham	were	invited	to	undergo	
unprepared	 flexible	 sigmoidoscopy	 to	 obtain	 high	 rectal/sigmoid	
biopsies	and	57	consented	to	this	additional	procedure.	Two	of	the	
samples	were	 immediately	 frozen	 in	 liquid	 nitrogen	 for	 analysis	 of	
serotonin	and	5‐HIAA	content	by	high‐performance	 liquid	chroma‐
tography	(HPLC),	two	in	RNALater	for	gene	expression	studies,	one	
for	 incubation	at	25°C	 in	95%	O2	 for	assay	of	5‐HT	release	from	a	
0‐30	minute	period	as	previously	described20	(Data	S1).	Finally,	one	
biopsy	was	 embedded	 in	 paraffin	 for	 routine	 histology	 to	 exclude	
microscopic	 colitis.	Real‐time	polymerase	 chain	 reaction	 (PCR)	was	
used	 to	assess	 the	 relative	expression	of	TPH1	with	 respect	 to	 the	
housekeeping	 gene	 hypoxanthine	 phosphoribosyltransferase	 1	
(HPRT1).	RNA	was	extracted	and	analysed	according	to	the	previously	
reported	method.21
2.4 | Plasma 5‐HIAA
We	 assessed	 fasting	 plasma	 5‐HIAA	 using	 HPLC	 as	 previously	
described.22
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2.5 | Genotyping
Blood	samples	were	taken	at	visit	1.	DNA	was	extracted	from	200	µl	
of	 citrated	 blood	 using	 the	QIAamp	DNA	Blood	Mini	 Kit	 (Qiagen	
Cat.	No.	51106)	and	subsequently	genotyped	 for	62	patients	who	
provided	 samples	 for	 the	 following	 polymorphisms:	 5‐HTTLPR	
(serotonin‐transporter‐linked	 polymorphic	 region)	 residing	 within	
the	 promoter	 region	of	 the	 serotonin	 transporter	 gene	SLC6A4	 as	
described	previously.23	Genotyping	of	the	SNPs	within	the	trypto‐
phan	hydroxylase	gene	TPH1	rs211105	(noncoding	SNP),	rs4537731	
(noncoding	SNP),	and	in	5‐HT3	receptor	genes	including	HTR3A	c.‐
42C	>	T	(rs1062613),	HTR3B	p.Y129S	(rs1176744),	HTR3C	p.N163K	
(rs6766410)	 and	HTR3E	 c.*76G	 >	 A	 (rs56109847)	was	 carried	 out	
by	 the	 KASPar®	 assay	 (KBiosciences,	 Ltd,	 Hoddesdon,	 United	
Kingdom)	using	KASP	by	design	primer	mixes	as	recommended	by	
the	manufacturer.	Thermal	cycling	was	performed	 in	Mastercycler	
vapo.protect	thermal	cyclers	(Eppendorf).	An	initial	15‐minute	incu‐
bation	at	95°C	was	followed	by	20	cycles	consisting	of	10	s	at	94°C,	
5	s	at	57°C	and	10	s	at	72°C,	followed	by	23	cycles	consisting	of	10	s	
at	94°C,	5	s	at	57°C	and	10	s	at	72°C.	After	thermal	cycling,	results	
were	analysed	using	the	fluorescence	plate	reader	of	the	7500	Fast	
Real‐Time	PCR	System	(Applied	Biosystems,	Foster	City,	California).	
About	 10%	 of	 the	 samples	 were	 repeated	 to	 ensure	 genotyping	
accuracy.
2.6 | Responder definition
Our	original	study	was	a	pilot	study,	so	we	used	stool	 form	rather	
than	pain	as	our	primary	endpoint	since	it	was	known	to	have	had	
a	much	 lower	 placebo	 response	 rate.	 Therefore,	 in	 this	 paper,	we	
used	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)	 definition	 of	 a	
“stool	 consistency	 responder”	 as	 a	 “patient	who	experiences	 a	50	
percent	or	greater	reduction	in	the	number	of	days	per	week	with	at	
least	one	stool	that	has	a	consistency	of	Type	6	or	7	compared	with	
baseline”.24	Our	pain	assessments	on	a	0‐3	scale	did	not	allow	us	to	
calculate	a	pain	responder	rate	according	to	FDA	guidelines	which	
were	published	after	our	study	was	initiated.
2.7 | Data analysis
Analysis	 was	 performed	 using	 Graphpad	 Prism	 version	 7.0c	
(GraphPad	Software,	La	Jolla	California,	USA).	Efficacy	parameters	
were	calculated	for	each	patient	as	the	difference	in	the	endpoints	
measured	in	the	last	2	weeks	of	the	ondansetron	and	placebo	periods.
Baseline	 and	 rectal	 biopsy	 data	were	 analysed	 for	 differences	
between	patients	and	healthy	volunteers	using	unpaired	t‐tests	and	
Mann‐Whitney	tests	on	parametric	and	nonparametric	data,	respec‐
tively.	Subsequent	analysis	based	on	their	stool	form	responder	sta‐
tus	and	mean	ondansetron	dose	was	done	as	below.
Genotype	data	was	correlated	with	stool	form	responder	status,	
baseline	 clinical	 features,	 biopsy	 results,	 final	 ondansetron	 dose,	
whole	 gut	 transit	 time	 and	 TPH1	 mRNA	 expression.	 Chi‐squared	
tests	were	performed	for	stool	form	responder	status,	and	one‐way	
ANOVA	and	Kruskal‐Wallis	tests	were	performed	on	parametric	and	
nonparametric	data	respectively.
3  | RESULTS
3.1 | Participants
Healthy	volunteers	were	age	and	sex	matched	to	patients.	Mean	pa‐
tient	and	control	ages	were	41	and	43	years	and	percentage	female	
were	71%	and	76%	respectively.	The	patients	taking	part	in	the	trial	
were,	as	expected,	more	anxious,	more	stressed	and	showed	greater	
somatic	symptoms	with	significantly	higher	HAD,	perceived	stress	
scale	and	PHQ‐12	scores	compared	to	controls	(Table	1).	There	were	
no	 differences	 between	 patients	 consented	 for	 biopsy	 and	 those	
TA B L E  1  Demographics	of	study	participants	showing	details	of	patients’	and	healthy	volunteers’	mental	health	and	bowel	function.	
There	were	no	significant	differences	between	those	undergoing	biopsy	and	those	choosing	not	to	have	this	extra	test
Variable
Patients without biopsy 
(n = 68)
Patients with biopsy 
(n = 57)
Heathy volunteers 
(n = 21) P value
Age 40	(12) 42	(12) 43	(18) .5921
Sex	(women),	n	(%) 53	(78) 36	(63) 16	(76) .1693
Patient	Health	Questionnaire	12 8	(3.5) 7.3	(3.7) 2.2	(1.8) <.0001
Anxiety 9.8	(4.3) 9.5	(4.8) 5.2	(2.7) .0001
Depression,	median	(IQR) 5.5	(3‐10) 4	(2‐8.8) 1	(1‐2) <.0001
Hospital	Anxiety	and	Depression	Scale 16.3	(7.4) 14.8	(8.2) 6.8	(3.3) <.0001
Perceived	Stress	Scale 19	(7.5) 17.5	(7.9) 11.2	(6.0) .0003
Bowel	frequency,	median	(IQR) 2.6	(1.9‐4) 2.8	(2‐4) 1.1	(1‐1.4) <.0001
Stool	form 5.4	(0.8) 5.4	(0.6) 3.5	(0.7) <.0001
Note: Data	are	mean	(SD),	unless	stated.	P	values,	were	significant,	demonstrate	differences	between	the	patient	population	and	healthy	volunteers	
with	no	difference	between	the	two	patient	groups.	P	values	are	obtained	from	one‐way	ANOVA	and	Kruskal‐Wallis	tests	for	parametric	and	non‐
parametric	data	respectively.
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who	did	not.	As	required	for	entry	into	the	trial10	IBS‐D	patients	re‐
ported	significantly	higher	bowel	frequency.
3.2 | Rectal biopsies
Rectal	biopsies	were	obtained	from	57	of	the	125	patients	complet‐
ing	the	trial	and	21	controls.	Biopsy	5‐HIAA	levels	were	significantly	
higher	 in	 IBS‐D	patients	 (Figure	1)	 as	were	 the	5‐HIAA	 /5‐HT	 ra‐
tios	 (Table	1).	There	were,	however,	no	 significant	differences	be‐
tween	patients	and	controls	for	biopsy	5‐HT	nor	5‐HT	release	in	the	
first	30	minutes	(see	Table	2).
3.3 | Plasma 5‐HIAA
Despite	higher	biopsy	levels,	median	plasma	5‐HIAA	(nmol/l)	was	
significantly	lower	in	patients	vs	controls	(16.2	vs	20.8,	P	<	.0001).
3.4 | Stool form responders
107/125	 IBS‐D	 patients	 completed	 daily	 stool	 diaries	 to	 allow	 as‐
sessment	 of	 response,	 of	 which	 82	 patients	 met	 FDA	 criteria	 for	
stool	form	responders.	As	shown	in	Table	3,	they	had	significantly	
lower	 baseline	 average	 abdominal	 pain	 scores	 and	 pain	 occurred	
on	fewer	days	per	week.	They	also	reported	lower	average	urgency	
scores	 and	 urgency	 on	 fewer	 days	 per	 week.	 Responders	 tended	
to	be	younger,	with	 lower	HAD	scores	and	to	have	slower	colonic	
transit;	however,	these	differences	failed	to	reach	conventional	sta‐
tistical	significance.	There	were	no	significant	differences	in	either	
baseline	stool	form	or	frequency	(Data	S1).
3.5 | Features of patients showing increased 
responsiveness to ondansetron (super‐responders)
About	39	IBS‐D	patients	adjusted	their	daily	dose	to	<	4	mg	on‐
dansetron	 per	 day,	 compared	 to	 55	 requiring	 a	 dose	 of	 ≥	 4	 mg	
ondansetron.	Patients	on	<	4	mg/d	(super‐responders)	were	more	
commonly	female	(92%	vs	58%,	P	=	 .003)	and	had	slightly	firmer	
baseline	stools	(5.1	vs	5.4,	P	=	.0159).	Other	baseline	clinical	fea‐
tures	including	pain,	urgency	and	bloating	as	assessed	from	days	
with	each	symptom	and	average	severity	scores;	HADS,	anxiety,	
depression	 and	 PHQ‐12	 scores	 were	 not	 significantly	 different	
(see	supplementary	data).
There	 were,	 however,	 significant	 differences	 in	 5‐HT	 con‐
centration	 in	 rectal	 biopsies	 which	 were	 significantly	 lower	 in	
super‐responders	 (21.3	 (17.0‐31.8)	vs	37.7,	 (21.4‐61.4),	P	=	 .0357)	
(Figure	2).	There	were	no	differences	between	the	groups	in	biopsy	
5‐HIAA,	 5‐HIAA	 /5‐HT,	 plasma	 5‐HIAA	 and	 biopsy	 TPH1	 mRNA	
expression	(Table	4).	However	super‐responders,	despite	the	lower	
dose,	showed	a	fourfold	greater	increase	in	whole	gut	transit	time	
when	on	ondansetron	compared	to	placebo	(15.6	vs	3.9,	P	=	.0398)	
(Figure	3).
F I G U R E  1  Colonic	biopsy	5‐hydroxyindole	acetic	acid	(5‐
HIAA)	concentrations	(median,	interquartile	range)	in	pmol/
mg	protein	in	IBS‐D	patients	(n	=	57)	and	healthy	volunteers	
(n	=	21);	***P = 0.0001
***
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Variable Patients (n = 57)
Healthy volunteers 
(n = 21) P value
biopsy	5‐HIAA	(pmol/mg	
protein)
2.1	(1.2‐4.2) 1.1	(0.4‐1.5) .0001
biopsy	5‐HIAA/5‐HT 0.06	(0.03‐0.16) 0.02	(0.02‐0.05) .0038
biopsy	5‐HT	(pmol/mg	protein) 31.2	(20.1‐46.0) 39.1	(16.5‐46.7) .9288
biopsy	5‐HT	release	in	30mins	
(pmol/mg	wet	weight)
17.2	(13.5‐23.1) 23.8	(13.8‐44.2) .078
Biopsy	5‐HT	release	in	30mins/	
Biopsy	5‐HT	content
0.8	(0.3‐1.1) 0.8	(0.2‐2.2) .851
Note: Data	are	median	(IQR).	P	values	obtained	from	Mann‐Whitney	tests.
TA B L E  2  Colonic	biopsy	5‐HIAA,	
5‐HT,	5‐HIAA/5‐HT,	and	5‐HT	release	
during	30	min	incubation	for	IBS‐D	
patients	and	healthy	volunteers
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3.6 | Effect of genotype on treatment response
Stool	form	responders	were	more	likely	to	carry	the	homozygous	CC	
genotype	p.N163K	rs6766410	of	the	HTR3C	gene	which	was	found	
in	33%	of	responders	compared	to	14%	of	nonresponders,	(P	=	.0066,	
Table	 5).	 The	 polymorphism	 in	 HTR3E	 c.*76G	 >	 A	 rs561098476	
showed	 a	 trend	 towards	 association	 with	 more	 responders	 carry‐
ing	the	GG	genotype	compared	to	nonresponders,	although	this	was	
nonsignificant	(P	=	.09,	see	supplementary	data).	Patients	carrying	the	
genotype	TT	of	the	HTR3A	SNP	rs1062613	reported	significant	im‐
provement	of	both	days	with	bloating	(1.7	(2.6)	vs	5.0	(2.5),	P	=	.035)	
and	average	bloating	score	(0.38	(0.7)	vs	1.4	(1.0),	P	=	.018).	The	sig‐
nificances	were	only	found	comparing	the	genotypes	TT	vs	CT,	and	
not	with	CT	vs	CC	or	TT	vs	CC,	probably	due	to	the	small	number	
of	TT	individuals	 (see	supplementary	data).	No	other	significant	as‐
sociations	with	any	of	the	genotypes	tested	were	found	for	the	sec‐
ondary	endpoints	such	as	5‐HT	or	5‐HIAA	 levels,	or	5‐HIAA/5‐HT	
ratio	(Table	S1).	Surprisingly	no	significant	effect	was	seen	for	the	two	
TPH1	SNPs	on	TPH1	mRNA	levels	(Data	S1).
3.7 | TPH1 mRNA expression
Seventy‐eight	patient	rectal	biopsies	were	analysed	for	TPH1	mRNA	
expression	levels.	There	were	no	significant	correlations	with	base‐
line	clinical	features,	biopsy	5‐HT	or	biopsy	5‐HIAA	concentrations	
(Data	S1).
Variable
Stool form 
responder 
(n = 82)
Stool form 
nonresponder 
(n = 25) P value
Age 40	(12) 45	(11) .0539
Sex	(female),	n	(%) 61	(74) 16	(64) .446
Hospital	Anxiety	and	Depression	Scale 14.7	(7.0) 17.8	(8.3) .0774
Patient	Health	Questionnaire	12 7.4	(3.4) 8.2	(3.9) .3189
Placebo	whole	gut	transit	(hours),	median	(IQR) 18	(9‐31) 10	(6.3‐24.8) .0625
Baseline	days	with	abdominal	pain,	median	(IQR) 5	(3‐7) 7	(5‐7) .0175
Baseline	average	abdominal	pain	score 1.2	(0.7) 1.8	(0.8) .0023
Baseline	days	with	urgency,	median	(IQR) 6	(4.8‐7) 7	(6.5‐7) .0014
Baseline	average	urgency	score,	median	(IQR) 1.4	(1‐2) 2.4	(1.6‐2.6) <.0001
Baseline	days	with	bloating,	median	(IQR) 6	(3‐7) 6	(3.5‐7) .498
Baseline	average	bloating	score 1.3	(0.8) 1.4	(0.9) .4438
Baseline	average	stool	form 5.3	(0.7) 5.5	(0.8) .2498
Baseline	average	stool	frequency,	median	(IQR) 2.6	(1.9‐3.9) 2.9	(1.9‐3.9) .7266
Biopsy	5‐HT	(pmol/mg	protein),	median	(IQR)a 28.6	(18.3‐42) 44.3	(25.5‐65.7) .0642
Biopsy	5‐HIAA	(pmol/mg	protein),	median	(IQR)a 2.1	(1‐4.1) 1.6	(1‐4) .6567
Biopsy	5‐HIAA	/5‐HT,	median	(IQR)a 0.06	(0.03‐0.20) 0.03	(0.02‐0.08) .2731
Plasma	5‐HIAA	(nmol/l),	median	(IQR)b 16.5	(13.1‐19.8) 16.3	(12.7‐18) .7022
Note: Data	are	mean	(SD)	unless	stated.	P	values	obtained	from	unpaired	t	tests	and	Mann‐Whitney	
tests	for	parametric	and	nonparametric	data	respectively.
Abbreviations:	5‐HT,	serotonin;	5‐HIAA,	5‐Hydroxyindoleacetic	acid.
aNumbers	in	each	group:	n	=	40	stool	form	responder;	n	=	9	stool	form	nonresponder.	
bNumbers	in	each	group:	n	=	53	stool	form	responder;	n	=	10	stool	form	nonresponder.	
TA B L E  3  Demographics,	psychological	
assessments,	stool	diary	results	and	
markers	of	serotonin	turnover	in	patients	
subdivided	into	those	who	met	FDA	“stool	
form	responder”	criteria	and	those	who	
did not
F I G U R E  2  Biopsy	serotonin	(5‐HT)	content	(median,	
interquartile	range)	in	pmol/mg	protein	subdivided	by	daily	dose	
showing	a	significantly	lower	biopsy	5‐HT	content	in	patients	
taking	<	4	mg	(n	=	17)	compared	with	those	taking	≥	4	mg	
ondansetron	daily	(n	=	32),	P	=	0.0357
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4  | DISCUSSION
Several	previous	studies	examining	different	aspects	of	serotonin	
metabolism	have	indicated	that	this	is	disturbed	in	IBS‐D	patients	
with	greater	post‐prandial	5‐HT	in	platelet‐poor	plasma22,25 and re‐
duced	SERT	mRNA	levels	in	both	duodenal20	and	colonic	biopsies	in	
some26 but not all27	studies.	The	current	study	found	significantly	
increased	 mucosal	 concentrations	 of	 the	 5‐HT	 metabolite	 5‐
HIAA	 together	with	an	 increased	5‐HIAA/	5‐HT	 ratio	 suggesting	
greater	turnover	of	mucosal	5‐HT	in	IBS‐D	patients.	Previous	evi‐
dence	excess	5‐HT	stimulates	secretion	and	motility,	this	provides	
a	rationale	for	the	use	of	both	TPH1	inhibitors28	and	5‐HT3 receptor 
antagonists	in	IBS‐D.	The	effectiveness	of	5‐HT3	receptor	antago‐
nists	 has	 been	 confirmed	 in	meta‐analyses3	which	 show	particu‐
lar	 benefit	 for	 urgency	 and	 loose	 stools.29	However,	 the	 number	
of	patients	needed	to	treat	to	get	one	responder	more	than	with	
placebo	is	7.7,	indicating	that	there	are	subgroups	of	individual	pa‐
tients	who	respond	better,	as	is	true	of	all	IBS	treatments.	Our	ini‐
tial	trial,	which	uniquely	allowed	patients	to	select	their	optimum	
dose,	 showed	striking	differences	 in	 the	doses	chosen,	with	over	
half	using	4	mg	or	less	per	day	while	some	used	the	maximum	al‐
lowed	of	24	mg/d.	These	differences	suggest	that	there	existed	a	
subgroup	with	 greater	 sensitivity	 to	ondansetron	which	we	have	
termed	“super‐responders”.	We,	therefore,	looked	to	see	what	bio‐
markers	predicted	“super‐responder	status”.
We	found	that	 rectal	biopsies	of	 the	super‐responders	had	a	sig‐
nificantly	lower	5‐HT	concentration	than	those	requiring	larger	doses.	
When	the	5‐HT	released	from	the	biopsies	over	30	minutes	was	ex‐
pressed	as	a	percentage	of	the	biopsy	5‐HT	concentration,	there	was	
a	trend	for	this	to	be	elevated	but	this	was	not	statistically	significant	
owing	to	wide	variability	in	this	measure.	Comparing	Tables	2	and	4	it	
can	be	seen	that	healthy	volunteers’	mucosal	5‐HT	values	were	similar	
to	the	group	requiring	≥	4	mg.	This	suggests	that	it	is	the	super‐respond‐
ers	who	have	abnormally	low	mucosal	5‐HT	though	the	other	5‐HT	pa‐
rameters	were	similar	to	both	healthy	controls	and	the	other	patients.
The	super‐responders	showed	a	four‐fold	greater	change	in	transit	
even	although	they	were	taking	a	dose	which	was	a	quarter	of	that	ob‐
served	in	those	requiring	larger	doses,	again	objectively	supporting	the	
idea	that	super‐responders	are	very	much	more	sensitive	to	the	drug.	
Variable
<4 mg  
ondansetron  
(n = 17)
≥4 mg  
ondansetron  
(n = 32) P value
Biopsy	5‐HT	(pmol/mg	protein) 21.3	(17.0‐31.8) 37.7	(21.4‐61.4) .0357
Biopsy	5‐HT	release	in	30	min	(pmol/mg	
wet	weight)
23.8	(10.9‐26.4) 17.1	(14‐21.8) .23
Biopsy	5‐HT	release	in	30	min/	Biopsy	
5‐HT	content
1.1	(0.6‐2.1) 0.4	(0.3‐0.8) .0818
Plasma	5‐HIAA	(nmol/l)a 17	(14.2‐20.0) 16.0	(12.3‐18.1) .1733
Biopsy	TPH1 mRNA relative expressionb 0.61	(0.54‐0.80) 0.61	(0.42‐0.95) .6554
Placebo	whole	gut	transit	time	(hours)c 18	(7‐30) 14	(7‐29) .7545
Difference	in	whole	gut	transit	time	on	
ondansetron	versus	placebo	(h)d
15.6	(1.8‐31) 3.9	(−5.1‐17.9) .0398
Note: Data	are	median	(IQR).	P	values	obtained	from	Mann‐Whitney	tests.
Abbreviations:	5‐HT,	serotonin;	5‐HIAA,	5‐Hydroxyindoleacetic	acid;	TPH1,	Tryptophan	hydroxy‐
lase	1.
aNumbers	in	each	group:	n	=	22	<4	mg	ondansetron;	n	=	41	≥4	mg	ondansetron.	
bNumbers	in	each	group:	n	=	17	<4	mg	ondansetron;	n	=	37	≥4	mg	ondansetron.	
cNumbers	in	each	group:	n	=	35	<4	mg	ondansetron;	n	=	51	≥4	mg	ondansetron.	
dNumbers	in	each	group:	n	=	33	<4	mg	ondansetron;	n	=	46	≥4	mg	ondansetron.	
TA B L E  4  Colonic	transit	and	markers	
of	colonic	mucosal	serotonin	turnover	
in	IBS‐D	patients,	subdivided	into	those	
requiring	<	4	mg	(super‐responders)	and	
those	requiring	≥	4	mg/d	of	ondansetron
F I G U R E  3  Difference	in	whole	gut	transit	(median,	interquartile	
range	in	hours)	while	taking	ondansetron	compared	to	placebo	
treatment,	subdivided	into	those	taking	<	4	mg	(n	=	33)	and	those	
taking	≥	4	mg	(n	=	46)	ondansetron	daily.	Despite	taking	a	lower	
dose	those	taking	<	4	mg	showed	a	significantly	greater	increase	in	
transit	time,	P	=	0.0398
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Having	less	serotonin	in	the	biopsy	could	be	either	because	of	reduced	
synthesis	 or	 accelerated	 turnover.	 The	 tendency	 for	 increased	5‐HT	
release	when	expressed	as	a	percentage	of	biopsy	serotonin	content,	
though	just	failing	to	reach	conventional	statistical	significance,	would	
tend	to	support	this	interpretation	and	might	explain	why	they	were	so	
much	more	sensitive	to	ondansetron	if	excess	5‐HT	was	driving	their	
symptoms.	Future	studies	might	use	in	vivo	assessment	of	5‐HT	release	
as	has	recently	been	done	in	animals	to	address	this	issue.30
The	striking	slowing	of	transit	seen	in	super‐responders	has	im‐
portant	 implications.	We	have	previously	 reported	 from	this	 same	
patient	group	that	 the	 faecal	protease	 levels	correlated	negatively	
with	transit	time	and	positively	with	average	urgency	 in	 IBS‐D	pa‐
tients.31	 As	 others	 have	 confirmed,	 urgency	 is	 strongly	 related	 to	
fast	transit	 in	 IBS‐D32	but	 just	exactly	why	slowing	transit	helps	 is	
uncertain.	We	hypothesise	that,	by	allowing	more	time	for	the	co‐
lonic	microbiota	to	deconjugate	bile	acids	and	degrade	endogenous	
proteases,31	the	slowing	of	transit	may	prevent	the	sensitisation	of	
the	rectum	that	these	endogenous	irritants	can	cause.	However,	fur‐
ther	intervention	trials	using	other	nonserotonergic	agents	to	slow	
transit,	such	as	loperamide,	will	be	needed	to	decide	what	is	unique	
about	the	5‐HT3	receptor	antagonist's	action.
Our	finding	that	stool	form	responders	were	more	likely	to	carry	
the	CC	genotype	p.N163K	rs6766410	of	HTR3C	 fits	with	the	data	
of	Fasching	et al9	which	suggested	CC	was	more	sensitive	 to	che‐
motherapy‐induced	vomiting,	 known	 to	be	driven	 largely	by	 sero‐
tonin.	This	substitution	has	a	predicted	possible	functional	effect	on	
the	receptor	(polyphen233	score	0.798).	If	those	with	CC	genotype	
are	more	sensitive	to	the	effects	of	5‐HT	this	might	help	explain	the	
benefit	of	a	drug	which	blocks	its	action.
Like	many	mechanistic	studies	which	make	substantial	demands	
on	patients	we	were	probably	underpowered	for	many	of	our	sec‐
ondary	 endpoints.	 Since	 our	 study	 was	 carried	 out	 on	 patients	
referred	to	secondary	care	they	can	only	be	generalised	to	this	pop‐
ulation	which	may	differ	 from	 that	 seen	 in	primary	 care.	We	only	
requested	biopsies	for	patients	recruited	in	Nottingham	where	the	
laboratory	facilities	and	staff	needed	were	available	and	we	allowed	
patients	to	choose	whether	to	have	the	extra	biopsies.	We	felt	that	
this	was	important	to	facilitate	recruitment	to	the	main	trial	and	as	
Table	 1	 shows,	we	 did	 not	 find	 any	 differences	 between	 patients	
who	opted	to	have	biopsies	compared	to	those	who	did	not,	so	we	
do	not	think	this	introduced	any	bias.
Although	we	chose	to	study	variants	in	the	HTR3C	gene	with	pre‐
vious	 evidence	 for	 potential	 influence	 on	 response	 to	 5‐HT,	 these	
findings	need	to	be	interpreted	with	caution	as	none	of	the	genetic	
analyses	were	corrected	for	multiple	testing	and	being	post	hoc	need	
to	be	replicated	before	they	can	be	accepted.	We	were	unable	to	link	
known	SNPs	in	the	genes	encoding	the	SERT	gene	SLC6A4 or TPH1 
with	a	clinically	significant	pattern	of	symptom	features	nor	respon‐
siveness	 to	 ondansetron,	 as	 has	 been	 suggested	 by	 others	 for	 the	
related	drug	ramosetron,34	but	our	numbers	were	probably	too	low	
for	such	an	analysis.	Also	relevant	 is	the	fact	that	we	did	not	find	a	
correlation between TPH1	SNPs	examined	and	mRNA	levels	for	TPH1. 
These	data	are	compatible	with	data	in	Gtex35	showing	that	rs21105	
has	no	significant	eQTL	signatures.	rs4537731	has	significant	eQTL	
signatures	in	skin	and	thyroid	but	not	in	nerve	or	gut	tissue.
Our	 pilot	 study	 asked	 subjects	 for	 pain	 scores	 on	 a	 0‐3	 scale,	
which	is	insufficient	to	define	a	decrease	in	pain	by	at	least	30%	as	
recommended	by	the	FDA.	Consequently,	we	defined	response	by	
the	change	in	stool	consistency	which	is	suboptimal	in	an	IBS	study.	
Future	 studies	 should	 take	 this	 into	 account	 by	 using	 an	 11‐point	
pain	scale	allowing	an	assessment	using	both	pain	and	stool	consis‐
tency	response	according	to	FDA	guidance.
While	psychological	factors	are	thought	to	be	important	in	IBS	
we	found	no	differences	in	anxiety	nor	somatisation	between	super‐
responders	 and	 non‐super‐responders,	 in	 keeping	 with	 ondanse‐
tron's	known	lack	of	central	effects.
Overall,	our	study	is	important	for	highlighting	the	heterogeneity	
of	IBS‐D	and	indicates	that	personalised	medicine	approach	is	both	
necessary	and	possible	if	we	know	the	mode	of	action	and	can	eas‐
ily	assess	the	key	factors	determining	response	to	particular	drugs.	
Variable
AA genotype 
(n = 15)
CA genotype 
(n = 54)
CC genotype 
(n = 28) P value
Stool	responder	(n	=	22),	% 14 53 33 .0066
Stool	nonresponder	(n	=	73),	% 18 68 14
Average	stool	form,	mean	(SD) 3.6	(1.5) 4.1	(1.3) 3.9	(1) .5143
Average	stool	frequency 2	(1.1‐3.1) 1.8	(1.4‐2.9) 1.6	(1.2‐2.4) .5892
Days	with	abdominal	pain 4	(1.4‐6.5) 6	(2.5‐7) 5	(1.5‐6.5) .0923
Average	abdominal	pain	score 0.6	(0.2‐1.4) 1.4	(0.6‐2.1) 0.9	(0.3‐1.3) .0241
Days	with	urgency 3.8	(2.3‐6.6) 5	(2.4‐6.5) 3	(1‐6.3) .2863
Average	urgency	score,	mean	(SD) 1.2	(1) 1.2	(0.8) 0.8	(0.7) .1276
Days	with	bloating 5	(2‐6.5) 5.8	(1.9‐7) 3	(0.5‐6.3) .207
Average	bloating	score 0.8	(0.1‐1.4) 1.4	(0.3‐2.1) 0.6	(0.1‐1.5) .1636
Note: Data	are	median	(IQR)	unless	stated.	P	values	for	clinical	features	while	on	ondansetron	are	
obtained	from	one‐way	ANOVA	and	Kruskal‐Wallis	tests	for	parametric	and	nonparametric	data	
respectively.	For	FDA	stool	responder	and	polymorphisms	the	P	value	is	obtained	from	a	Chi‐
squared	test.
TA B L E  5  Effect	of	the	polymorphism	
HTR3C	p.N163K	rs6766410	on	IBS‐D	
patients’	FDA	stool	responder	status,	
expressed	as	a	percentage	of	responder	
status	patient	population;	and	clinical	
features	while	on	ondansetron
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Rectal	 biopsy	5‐HT	might	 be	 such	 a	 parameter	 for	 5‐HT	 receptor	
3	antagonists,	however,	rectal	biopsy	assessment	of	5‐HT	turnover	
is	not	currently	a	feasible	clinical	test.	The	 immediate	value	of	our	
findings	 is	 that	 it	encourages	us	 to	 further	subdivide	 IBS‐D.	Some	
plainly	have	serotonin	excess,	but	others	appear	to	have	quite	differ‐
ent	mechanisms	such	as	excessive	secretions	or	impaired	absorption	
which	we	should	explore	further.	Examining	the	response	to	4	mg	
daily	of	ondansetron	could	be	a	simple	test	to	identify	at	least	one	
subgroup	which	is	not	currently	readily	identifiable.	Future	studies	
of	other	nonserotonergic	agents	might	use	this,	as	we	currently	do	
with	a	trial	of	colestyramine,	to	exclude	patients	with	a	known	mech‐
anism	of	diarrhoea	and	 thus	 improve	 response	 rates	 to	 the	newer	
agents	under	trial.
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